A screening method that combines a traditional PSA test with an MRI detects a significantly greater number of prostate cancer cases and improves diagnostic accuracy. The study was conducted as part of the largest international research project on prostate cancer. The method will now be tried with 40,000 subjects in Gothenburg.
1+1= Focal1. Only a matter of time.
A cancer remover, no medicine, no nausea, no hair loss, no long visits to the cancer clinic, no pic, no bags hanging by your chair etc. Not too much longer now.
Are you saying the only difference between the phase 2 trial and the "PRESENT" phase 3 is additional participants?
Don't think management is planning on selling. If they were they would not be spending/building out the sales program.
Management thinks (imo) they have a chance to make a name for themselves in the Bio world, I hope it works out this way.
Just read article on the cuban vaccine for lung cancer, 4 months longer life expectancy? Surely if I had lung cancer I would go for every day possible. However, not much of a vaccine in my eyes. The media is going apes over this major breakthrough ........out time will come and it won't be a few months longevity for the women having BC it will be years or more.
NeuVax is safe. A big plus when it comes to treating cancer, name another drug or treatment that comes with minimal or no side effects, maybe HIFU but that is a treatment not a injected drug.
Any idea on the up front fee the partner would throw in? Could we have a possible bidding war between interested companies? Also the market's reaction to a partner with "cred" could send Galena to "happy happy happy" PPS $$$. Back to reality, patience and block out the noise, ride the wave if it happens.
How much more information does the management have than everybody else concerning the ongoing "present" trial? If the study is double blinded nobody knows until info is released. Not saying that management is not talking with interested companies locateed in S.F. (nice place to visit but not live there).
Ever give it thought that another company may be trying to control the share price by hiring out these annoying negativites? Wham, Bam, thank you for the cheap company and Neuvax. Anything is possible.
Scientists have identified a way to potentially predict which patients with an early form of breast cancer will experience disease progression. Ductal carcinoma in situ (DCIS) is a precursor of breast cancer where the cancerous cells are contained within the milk-making ducts. Without treatment, commonly a combination of breast-conserving surgery and radiotherapy, up to a half of patients will have their disease come back, either as DCIS or as invasive breast cancer.
The HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65% over the period 2014-2019.
The FDA will jump to approve any positive treatment for this insidious disease.
Breast cancer is the most common cancer in the UK, affecting more than 45,500 women every year.
The UK is a small island in a world full of women with potential breast cancer indications.